fashion -WSS

fashion

author：hotspot 2025-09-30 17:27:26 - browse：14

A gene therapy study, halted when four children with a rare neuromuscular disorder died after treatment, showed enough promise to merit finding a path forward, according to the medicine’s manufacturer.

The treatment, made by the Japanese pharmaceutical company Astellas, led to severe and fatal liver problems for four of the 24 treated children with X-linked myotubular myopathy, or XLMTM, a genetic disease that severely degrades muscle function and kills most patients before the age of 10. Three died in 2020; the fourth died a year later.

In an analysis of its clinical trial, published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. The hope, for Astellas and for families affected by XLMTM, is that the company can find a safe way to proceed and convince the Food and Drug Administration to allow it to resume development.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： A deep dive into Applied Therapeutics’ data, and questions on Cassava

knowledge

WSS

What we need to know about Arena Bioworks

Vertigo drug brings hope for rare neuron disorder, Niemann

First medicine developed to treat MASH expected to be approved soon

Biden administration opens offers in Medicare drug price negotiations

A $475,000 price tag for a new cancer drug: crazy or meh?

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

focus

fashion

focus

Medical leaders decry Supreme Court decision on affirmative action

A deep dive into Applied Therapeutics’ data, and questions on Cassava

In Memoriam: Notable people who died in 2023

Cognito secures funding to test medical device for Alzheimer's

Wildfire smoke exposes gaps in outdoor worker protections

Amylyx ALS drug fails large clinical trial

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Headspace, Meta partner to launch VR meditation app for Quest

Sports medicine is finally prioritizing gender equality

With psoriasis trial ahead, Alumis raises $259 million

knowledge

The lessons of Aduhelm, an Alzheimer's drug that was not to be

ARCH Venture Partners is raising $3 billion for a life sciences fund

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Do digital therapeutics have a future in medicine?

IVF, abortion rights issues kick off Biden’s State of the Union

Vertex non

hotspot

focus

knowledge

hotspot